Shawn K. Singh's most recent trade in VistaGen Therapeutics Inc was a trade of 7,541 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.70 per share. | 30 Jun 2025 | 7,541 | 18,028 (0%) | 0% | 1.7 | 12,820 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2025 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 2.96 per share. | 28 Jun 2024 | 4,854 | 10,487 (0%) | 0% | 3.0 | 14,358 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Singh K. Shawn | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 1.72 per share. | 29 Dec 2023 | 167 | 5,633 (0%) | 0% | 1.7 | 287 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 1.59 per share. | 30 Jun 2023 | 167 | 5,466 (0%) | 0% | 1.6 | 265 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.09 per share. | 30 Dec 2022 | 5,000 | 158,998 (0%) | 0% | 0.1 | 438 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 0.17 per share. | 17 Aug 2022 | 600,000 | 626,234 (1%) | 1% | 0.2 | 103,200 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.75 per share. | 30 Jun 2022 | 5,000 | 153,998 (0%) | 0% | 0.7 | 3,740 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. | 12 May 2022 | 100,000 | 148,998 (0%) | 0% | 1 | 100,000 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2022 | 100,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 1.95 per share. | 30 Jun 2021 | 5,000 | 45,375 (0%) | 0% | 1.9 | 9,733 | Common Stock |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2021 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Shawn K. Singh | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 23 Apr 2021 | 5,000 | 40,375 (0%) | 0% | 1.5 | 7,500 | Common Stock |